[go: up one dir, main page]

AR023201A1 - PÉPTIDO CíCLICO, ANÁLOGO DE PÉPTIDO CíCLICO, Y COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE. - Google Patents

PÉPTIDO CíCLICO, ANÁLOGO DE PÉPTIDO CíCLICO, Y COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE.

Info

Publication number
AR023201A1
AR023201A1 ARP000101405A ARP000101405A AR023201A1 AR 023201 A1 AR023201 A1 AR 023201A1 AR P000101405 A ARP000101405 A AR P000101405A AR P000101405 A ARP000101405 A AR P000101405A AR 023201 A1 AR023201 A1 AR 023201A1
Authority
AR
Argentina
Prior art keywords
cyclic peptide
understands
pharmaceutical composition
receptor
disorders
Prior art date
Application number
ARP000101405A
Other languages
English (en)
Inventor
Russell James Sheldon
Jeremy Donald Wang
Adam Wieslaw Mazur
Frank Ebetino
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR023201A1 publication Critical patent/AR023201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Se revelan ligandos de receptores MC-4 y MC-3 que tienen una estructura segun la formula (1), en donde B, X, Z, D, G, R, R1, R1, R11, m, n, p, y q soncomo se describe en la especificacion. Los compuestos son utiles en el tratamiento de enfermedadesq ue son mediadas por el receptor MC-4 y/o el receptor MC-3.Como tal, la invencion está dirigida a métodos de tratar trastornos del peso corporal, tales como obesidad, anorexia y caquexia. La invencion tambiénse refiere al tratamiento de ladepresion d el sistema nervioso central, trastornos relacionados con el comportamiento, trastornos relacionados con la memoria,funcion cardiovascular, inflamacion, sepsis y choque séptico, chocque cardiogénico, choque hipovolémico, disfuncionsexual, disfuncion erectil,atrofia muscular, enfermedades asociadas con el crecimiento y reparacion de los nervios, y crecimiento fetal intrauterino. También se revelan composicionesfarmacéuticas que comprenden los compuestos de la formula (1).
ARP000101405A 1999-03-29 2000-03-29 PÉPTIDO CíCLICO, ANÁLOGO DE PÉPTIDO CíCLICO, Y COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE. AR023201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12667399P 1999-03-29 1999-03-29

Publications (1)

Publication Number Publication Date
AR023201A1 true AR023201A1 (es) 2002-09-04

Family

ID=22426131

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101405A AR023201A1 (es) 1999-03-29 2000-03-29 PÉPTIDO CíCLICO, ANÁLOGO DE PÉPTIDO CíCLICO, Y COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE.

Country Status (34)

Country Link
US (2) US6613874B1 (es)
EP (1) EP1165613B1 (es)
JP (1) JP2002542159A (es)
KR (2) KR100519201B1 (es)
CN (1) CN1249086C (es)
AR (1) AR023201A1 (es)
AT (1) ATE393783T1 (es)
AU (1) AU763510B2 (es)
BR (1) BR0009497A (es)
CA (1) CA2368431C (es)
CO (1) CO5170531A1 (es)
CZ (1) CZ20013407A3 (es)
DE (1) DE60038734T2 (es)
DK (1) DK1165613T3 (es)
ES (1) ES2304345T3 (es)
HK (1) HK1044954B (es)
HU (1) HUP0202203A3 (es)
ID (1) ID30262A (es)
IL (1) IL145406A0 (es)
MA (1) MA25403A1 (es)
MX (1) MXPA01009881A (es)
MY (1) MY126585A (es)
NO (1) NO20014568L (es)
NZ (1) NZ514141A (es)
PE (1) PE20001641A1 (es)
PL (1) PL350095A1 (es)
PT (1) PT1165613E (es)
RU (1) RU2213098C2 (es)
SA (1) SA00210192B1 (es)
SK (1) SK13082001A3 (es)
TR (1) TR200102765T2 (es)
TW (1) TWI250990B (es)
WO (1) WO2000058361A1 (es)
ZA (1) ZA200107411B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
EP1187614A4 (en) 1999-06-04 2005-06-22 Merck & Co Inc SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
AU2001229491A1 (en) * 2000-01-18 2001-07-31 Merck And Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
ES2280393T3 (es) 2000-08-30 2007-09-16 F. Hoffmann-La Roche Ag Peptidos ciclicos que tienen actividad agonista para el receptor de melanocortin-4.
JP2004509974A (ja) * 2000-09-27 2004-04-02 ザ　プロクター　アンド　ギャンブル　カンパニー メラノコルチンの受容体リガンド
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
CN101497654A (zh) * 2003-09-30 2009-08-05 诺沃挪第克公司 黑皮素受体激动剂
EP1997828B1 (en) * 2003-11-05 2017-10-04 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides from BCL-2 and uses thereof
AU2015201062B2 (en) * 2003-11-05 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
EP1804798A4 (en) * 2004-10-05 2008-01-23 Merck & Co Inc METHOD FOR THE TREATMENT OF SUBSTANCE ABUSE AND SEARCH
WO2006060873A1 (en) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
EP2286825B1 (en) * 2005-07-08 2016-09-28 Ipsen Pharma Melanocortin receptor ligands
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
EP1968995A1 (en) * 2005-12-30 2008-09-17 F. Hoffmann-la Roche AG Methods for the synthesis of arginine-containing peptides
HUE029016T2 (en) 2006-06-09 2017-02-28 Synact Pharma Aps Phenylpyrrolidinoguanidine derivatives
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2398310T3 (es) 2007-02-23 2013-03-15 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
KR101623985B1 (ko) * 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
JP5250026B2 (ja) 2007-05-25 2013-07-31 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ヒダントインで修飾したメラノコルチン受容体リガンド
JP2011511076A (ja) * 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド 治療用ペプチド模倣大環状分子
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
EP2310407A4 (en) * 2008-04-08 2011-09-14 Aileron Therapeutics Inc BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
JP2012503025A (ja) 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド 精製されたポリペプチド組成物を調製するための方法
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010144344A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
JP2013510881A (ja) * 2009-11-16 2013-03-28 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ａｃ−Ａｒｇ−シクロ（Ｃｙｓ−Ｄ−Ａｌａ−Ｈｉｓ−Ｄ−Ｐｈｅ−Ａｒｇ−Ｔｒｐ−Ｃｙｓ）−ＮＨ２の合成のための方法
WO2011063367A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
CN101824415A (zh) * 2010-03-31 2010-09-08 华东师范大学 黑素皮质1型受体基因的snp及其应用
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
PT2920197T (pt) 2012-09-26 2021-06-11 Harvard College Péptidos agrafados com bloqueio de prolina e suas utilizações
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3782638A1 (en) 2013-03-13 2021-02-24 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
AU2014278005B2 (en) 2013-06-14 2018-11-22 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3145523A4 (en) 2014-05-21 2018-02-21 President and Fellows of Harvard College Ras inhibitory peptides and uses thereof
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
HUE059638T2 (hu) 2019-05-10 2022-12-28 Synact Pharma Aps Ízületi gyulladásos betegségek kombinált kezelése
CN110681362B (zh) * 2019-09-26 2020-09-11 浙江大学 以羧基和吲哚基为功能基团的混合模式层析介质
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
US11932628B2 (en) 2021-01-04 2024-03-19 Regents Of The University Of Minnesota Selective small molecule peptidomimetic melanocortin ligands
KR20240024177A (ko) 2021-06-21 2024-02-23 신액트 파마 에이피에스 페닐 피롤 아미노구아니딘의 염 및 페닐 피롤 아미노구아니디늄 염의 다형체

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462927A (en) 1985-04-30 1995-10-31 The Administrators Of The Tulane Educational Fund Peptides aiding nerve regeneration
DE3851002T2 (de) 1987-05-22 1995-02-02 University Patents, Inc., Westport, Conn. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
JP2795449B2 (ja) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
ZA908610B (en) 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
ES2089256T3 (es) 1991-02-15 1996-10-01 Takeda Chemical Industries Ltd Antagonista de la endotelina.
DE69220861T2 (de) 1991-08-13 1997-11-20 Takeda Chemical Industries Ltd Zyklische Peptide und ihre Verwendung
RU2096415C1 (ru) * 1991-09-30 1997-11-20 Дзе Дюпон Мерк Фармасьютикал Компани Циклические пептиды или их фармацевтически приемлемые соли, фармацевтическая композиция
EP0552417B1 (en) 1991-11-19 1999-07-07 Takeda Chemical Industries, Ltd. Cyclic peptides and use thereof
EP0547317A1 (en) 1991-12-19 1993-06-23 Takeda Chemical Industries, Ltd. Endothelin antagonists
DE9203901U1 (de) 1992-03-24 1992-07-16 Croon & Lucke Maschinenfabrik Gmbh, 7947 Mengen Gestell zum Lagern von flächigen Werkstücken
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
DE69330868T2 (de) 1992-07-27 2002-04-25 Biomeasure, Inc. Antagonisten des neuromedin b rezeptors
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
EP0714909A1 (en) 1994-12-01 1996-06-05 Takeda Chemical Industries, Ltd. Composition for prophylaxis or treatment of pulmonary circulatory diseases
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
CN1183104A (zh) 1995-04-28 1998-05-27 武田药品工业株式会社 Lh－rh受体拮抗剂
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
ATE233098T1 (de) 1996-06-11 2003-03-15 Novartis Ag Kombination eines somatostatin analogs und eines rapamycins
EP0967222A4 (en) 1996-06-25 2001-08-22 Nisshin Flour Milling Co CYCLIC DEPSIPEPTIDES AND MEDICINES CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENT
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
JP2001506996A (ja) 1996-12-17 2001-05-29 クアドラント ホールディングス ケンブリッジ リミテッド メラノコルチン受容体３、４又は５の特異結合のためのメラノコルチン誘導体
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight

Also Published As

Publication number Publication date
TR200102765T2 (tr) 2002-05-21
CA2368431C (en) 2006-01-24
MXPA01009881A (es) 2002-05-06
KR20050009722A (ko) 2005-01-25
HK1044954B (en) 2008-11-21
IL145406A0 (en) 2002-06-30
NO20014568D0 (no) 2001-09-20
HK1044954A1 (en) 2002-11-08
KR100558131B1 (ko) 2006-03-10
TWI250990B (en) 2006-03-11
US6951916B2 (en) 2005-10-04
HUP0202203A3 (en) 2003-09-29
JP2002542159A (ja) 2002-12-10
KR100519201B1 (ko) 2005-10-06
NO20014568L (no) 2001-11-29
NZ514141A (en) 2004-01-30
ID30262A (id) 2001-11-15
MY126585A (en) 2006-10-31
CZ20013407A3 (cs) 2002-02-13
CA2368431A1 (en) 2000-10-05
MA25403A1 (fr) 2002-04-01
US20040023859A1 (en) 2004-02-05
ZA200107411B (en) 2002-05-29
PT1165613E (pt) 2008-07-29
DK1165613T3 (da) 2008-08-25
WO2000058361A1 (en) 2000-10-05
CN1345335A (zh) 2002-04-17
KR20020008143A (ko) 2002-01-29
SK13082001A3 (sk) 2002-03-05
AU763510B2 (en) 2003-07-24
DE60038734D1 (de) 2008-06-12
DE60038734T2 (de) 2009-07-02
ATE393783T1 (de) 2008-05-15
ES2304345T3 (es) 2008-10-16
PE20001641A1 (es) 2001-02-07
EP1165613A1 (en) 2002-01-02
CN1249086C (zh) 2006-04-05
BR0009497A (pt) 2002-01-15
HUP0202203A2 (en) 2002-10-28
EP1165613B1 (en) 2008-04-30
US6613874B1 (en) 2003-09-02
RU2213098C2 (ru) 2003-09-27
PL350095A1 (en) 2002-11-04
AU4017900A (en) 2000-10-16
SA00210192B1 (ar) 2006-06-04
CO5170531A1 (es) 2002-06-27

Similar Documents

Publication Publication Date Title
AR023201A1 (es) PÉPTIDO CíCLICO, ANÁLOGO DE PÉPTIDO CíCLICO, Y COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE.
ATE435855T1 (de) Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
UY28150A1 (es) Agentes terapeuticos
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
MY141476A (en) 5ht2c receptor modulators
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
BRPI0814382A2 (pt) Composto, uso do composto, e, composição farmacêutica
EA200801738A1 (ru) Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
NI200700156A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurológicos
GEP20053710B (en) Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
PL396711A1 (pl) Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
BG107865A (en) Substituted pyridoindoles as serotonin agonists and antagonists
HUP0301351A2 (hu) Helyettesített dipeptidszármazékok eljárás az előállításukra alkalmazásuk növekedési hormon szekretagóg hatóanyagokként, és ezeket tartalmazó gyógyszerkészítmények
PA8556901A1 (es) Nuevos derivados de piperazina
WO2005030128A3 (en) Pyrazole modulators of metabotropic glutamate receptors
CR9389A (es) Compuestos de imidazopiridazina
TW200531689A (en) Therapeutic agents
CR8759A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores quimioquinas
CR10236A (es) Modulares del indol sulfonamida de receptores de progesterona
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
TW200635903A (en) Therapeutic agents
EA200600188A1 (ru) Производные пиримидин-2,4-диона и их применение в качестве антагонистов рецепторов гонадолиберина
WO2004087048A3 (en) Benzamide modulators of metabotropic glutamate receptors

Legal Events

Date Code Title Description
FG Grant, registration